ALINA: fewer patients stopped adjuvant alectinib than chemotherapy; quality-of-life gains held to two years

Creatine phosphokinase increases on alectinib, neutropenia on chemotherapy

The two treatment groups produced different grade 3–4 adverse events, and the difference follows the mechanism of each regimen. In the alectinib group the most common were increased blood creatine phosphokinase in eight of 128 patients (6%), increased alanine aminotransferase in two (2%) and increased blood bilirubin in two (2%). In the chemotherapy group they were decreased neutrophil count in 12 of 120 patients (10%), neutropenia in ten (8%) and nausea in five (4%).

The authors describe the safety of adjuvant alectinib as generally consistent with its known profile. That is the relevant question for an adjuvant indication, where the drug is given for 24 months to patients who have no detectable cancer, and where tolerability governs whether a patient completes the course.

Two serious treatment-related events on alectinib, eight on chemotherapy

Serious treatment-related adverse events occurred in two of the 128 patients treated with alectinib, one case of appendicitis and one of pneumonitis. Eight of the 120 patients treated with chemotherapy had one, most commonly gastrointestinal disorders in three patients (3%). No deaths attributed to adverse events occurred in either group.

Discontinuation is the measure that matters most for an adjuvant drug, because a patient who stops early loses the treatment effect the trial was built on. Seven patients (5%) discontinued alectinib because of adverse events. Fifteen (13%) discontinued chemotherapy. The abstract does not report how many alectinib patients required a dose reduction or interruption without stopping, which would describe the cost of staying on treatment for the two years.

A safety comparison drawn across 24.8 months and 3.7 months

The two safety datasets do not cover comparable periods. Median safety follow-up was 24.8 months in the alectinib group and 3.7 months in the chemotherapy group, because the trial gave alectinib for 24 months and chemotherapy for four 3-week cycles, and assessed safety until 28 days after the last dose in each case. Patients on alectinib were therefore observed for adverse events for close to seven times as long as patients on chemotherapy.

The difference in observation time is worth holding in view when the two columns of adverse-event rates are read side by side, since the groups were not watched for equal periods. The abstract reports the raw proportions in each group and does not report exposure-adjusted rates, which is the analysis that would put the two groups on a common footing.

Five SF-36v2 domains improved by week 12, and summary scores reached the general population norm

Health-related quality of life was measured with the SF-36v2 questionnaire at baseline, every three weeks to week 12, then every 12 weeks until recurrence, withdrawal of consent, death or week 96. Norm-based scoring was applied, and clinically meaningful changes were defined using the SF-36v2 manual rather than by a threshold the trial set for itself.

At week 12, alectinib produced a clinically meaningful difference in improvement from baseline in five domains: bodily pain, role physical, mental health, social functioning and vitality. Improvements in physical and mental quality of life were maintained across the two years of active treatment. At week 96 the mean Mental Component Summary score was 49.9 (SD 10.4) and the mean Physical Component Summary score was 48.8 (SD 7.2), close to the general population norm of 50. A patient two years into adjuvant treatment was, on these scores, reporting health much like someone drawn from the general population.

“For patients with resected ALK-positive NSCLC, adjuvant alectinib had a manageable safety profile; HRQoL improved and was maintained over 2 years of active treatment.”Dziadziuszko et al., The Lancet Oncology (2026)

An exploratory endpoint, with the quality-of-life comparison left undescribed in the abstract

The trial itself places these outcomes below its primary question. Disease-free survival was the primary endpoint and was reported previously, safety was a secondary endpoint, and health-related quality of life was exploratory. That ordering is the authors’ own, and it sets how much weight the week 12 domain findings can carry: they describe what patients reported, in a comparison the trial did not designate as confirmatory.

Several figures a reader would want are absent from the abstract. It reports no questionnaire completion rates over the 96 weeks, which govern how much the later timepoints can bear, and no numeric domain scores at week 12 for either group. It also gives no summary scores for the chemotherapy group at any timepoint, so the week 96 figures stand on their own rather than against a comparator. The trial remains ongoing.